» Articles » PMID: 24997860

Cancer Survival Classification Using Integrated Data Sets and Intermediate Information

Overview
Date 2014 Jul 7
PMID 24997860
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Although numerous studies related to cancer survival have been published, increasing the prediction accuracy of survival classes still remains a challenge. Integration of different data sets, such as microRNA (miRNA) and mRNA, might increase the accuracy of survival class prediction. Therefore, we suggested a machine learning (ML) approach to integrate different data sets, and developed a novel method based on feature selection with Cox proportional hazard regression model (FSCOX) to improve the prediction of cancer survival time.

Methods: FSCOX provides us with intermediate survival information, which is usually discarded when separating survival into 2 groups (short- and long-term), and allows us to perform survival analysis. We used an ML-based protocol for feature selection, integrating information from miRNA and mRNA expression profiles at the feature level. To predict survival phenotypes, we used the following classifiers, first, existing ML methods, support vector machine (SVM) and random forest (RF), second, a new median-based classifier using FSCOX (FSCOX_median), and third, an SVM classifier using FSCOX (FSCOX_SVM). We compared these methods using 3 types of cancer tissue data sets: (i) miRNA expression, (ii) mRNA expression, and (iii) combined miRNA and mRNA expression. The latter data set included features selected either from the combined miRNA/mRNA profile or independently from miRNAs and mRNAs profiles (IFS).

Results: In the ovarian data set, the accuracy of survival classification using the combined miRNA/mRNA profiles with IFS was 75% using RF, 86.36% using SVM, 84.09% using FSCOX_median, and 88.64% using FSCOX_SVM with a balanced 22 short-term and 22 long-term survivor data set. These accuracies are higher than those using miRNA alone (70.45%, RF; 75%, SVM; 75%, FSCOX_median; and 75%, FSCOX_SVM) or mRNA alone (65.91%, RF; 63.64%, SVM; 72.73%, FSCOX_median; and 70.45%, FSCOX_SVM). Similarly in the glioblastoma multiforme data, the accuracy of miRNA/mRNA using IFS was 75.51% (RF), 87.76% (SVM) 85.71% (FSCOX_median), 85.71% (FSCOX_SVM). These results are higher than the results of using miRNA expression and mRNA expression alone. In addition we predict 16 hsa-miR-23b and hsa-miR-27b target genes in ovarian cancer data sets, obtained by SVM-based feature selection through integration of sequence information and gene expression profiles.

Conclusion: Among the approaches used, the integrated miRNA and mRNA data set yielded better results than the individual data sets. The best performance was achieved using the FSCOX_SVM method with independent feature selection, which uses intermediate survival information between short-term and long-term survival time and the combination of the 2 different data sets. The results obtained using the combined data set suggest that there are some strong interactions between miRNA and mRNA features that are not detectable in the individual analyses.

Citing Articles

Pancreatic Cancer Survival Prediction: A Survey of the State-of-the-Art.

Bakasa W, Viriri S Comput Math Methods Med. 2021; 2021:1188414.

PMID: 34630626 PMC: 8497168. DOI: 10.1155/2021/1188414.


A primer on machine learning techniques for genomic applications.

Monaco A, Pantaleo E, Amoroso N, Lacalamita A, Lo Giudice C, Fonzino A Comput Struct Biotechnol J. 2021; 19:4345-4359.

PMID: 34429852 PMC: 8365460. DOI: 10.1016/j.csbj.2021.07.021.


EARN: an ensemble machine learning algorithm to predict driver genes in metastatic breast cancer.

Mirsadeghi L, Haji Hosseini R, Banaei-Moghaddam A, Kavousi K BMC Med Genomics. 2021; 14(1):122.

PMID: 33962648 PMC: 8105935. DOI: 10.1186/s12920-021-00974-3.


Identification of the miRNA signature associated with survival in patients with ovarian cancer.

Yerukala Sathipati S, Ho S Aging (Albany NY). 2021; 13(9):12660-12690.

PMID: 33910165 PMC: 8148489. DOI: 10.18632/aging.202940.


SurvNet: A Novel Deep Neural Network for Lung Cancer Survival Analysis With Missing Values.

Wang J, Chen N, Guo J, Xu X, Liu L, Yi Z Front Oncol. 2021; 10:588990.

PMID: 33552965 PMC: 7855857. DOI: 10.3389/fonc.2020.588990.